Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.
Viral infections including cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus are a common and predictable problem in transplant recipients. While cellular immune therapies have been successfully used to tackle infectious complications in transplant recipients, manufacturing immunotherapies to address the multitude of possible pathogens can be technically challenging and labor-intensive. Here we describe a novel adenoviral antigen presentation platform (Ad-MvP) as a tool for rapid generation of multivirus-specific T-cells in a single step. Ad-MvP encodes 32 CD8+ T-cell epitopes from cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus as a contiguous polyepitope. We demonstrate that Ad-MvP vector can be successfully used for rapid in vitro expansion of multivirus-specific T-cells from transplant recipients and in vivo priming of antiviral T-cell immunity. Most importantly, using an in vivo murine model of Epstein-Barr virus-induced lymphoma, we also show that adoptive immunotherapy with Ad-MvP expanded autologous and allogeneic multivirus-specific T-cells is highly effective in controlling Epstein-Barr virus tumor outgrowth and improving overall survival. We propose that Ad-MvP has wide ranging therapeutic applications in greatly facilitating in vivo priming of antiviral T-cells, the generation of third-party T-cell banks as "off-the-shelf" therapeutics as well as autologous T-cell therapies for transplant patients.
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory , Brisbane, Australia.
Vijayendra
V
Dasari
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory , Brisbane, Australia.
Andrea
A
Schuessler
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory , Brisbane, Australia.
Corey
C
Smith
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory, Brisbane, Australia; Human Immunity Laboratory, Brisbane, Australia.
Yide
Y
Wong
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory, Brisbane, Australia; Human Immunity Laboratory, Brisbane, Australia.
John J
JJ
Miles
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory, Brisbane, Australia; Immunology in Cancer and Infection Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Australia; School of Medicine, The University of Queensland, Brisbane, Australia.
Mark J
MJ
Smyth
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory , Brisbane, Australia.
George
G
Ambalathingal
Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, Australia; School of Medicine, The University of Queensland, Brisbane, Australia.
Ross
R
Francis
Department of Nephrology, Princess Alexandra Hospital , Woolloongabba, Australia.
Scott
S
Campbell
Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; School of Medicine, The University of Queensland, Brisbane, Australia.
Daniel
D
Chambers
QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory, Brisbane, Australia; School of Medicine, The University of Queensland, Brisbane, Australia.
Rajiv
R
Khanna